Latest Pulmonology Articles

• High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure June 4, 2026
  In a multicenter trial involving patients with acute hypoxemic respiratory failure, 28-day mortality with high-flow oxygen was not significantly different from that with standard oxygen.
  Jean-Pierre Frat, Jean-Pierre Quenot, Christophe Guitton, Rémi Coudroy, Arnaud Gacouin, Julio Badie, Alexandre Demoule, Damien Contou, Guillaume Carteaux, Stephan Ehrmann, Fabien Jarousseau, Nicholas Sedillot, Jean-Philippe Rigaud, Jean Reignier, François Beloncle, Anne-Florence Dureau, Alexis Ferré, Cédric Daubin, Anna Bourreau, Agathe Delbove, Gaël Pradel, Abdelhamid Fatah, Gwenhael Colin, Guillaume Deniel, Olivier Lamouret, Béatrice La Combe, Gwénaël Prat, Louis-Marie Galerneau, Gaël Bourdin, Gautier Julien, Anaïs Curtiaud, Mélanie Saint-Léger, Emanuele Turbil, Faustine Reynaud, Louis Chamblet, Stéphanie Ragot, Arnaud W. Thille, the SOHO Trial Group and the REVA Network*
• Rethinking High-Flow Oxygen in Acute Hypoxemic Respiratory Failure June 4, 2026
  Acute hypoxemic respiratory failure remains one of the most common conditions encountered in the intensive care unit (ICU).1 During the past decade, high-flow nasal oxygen has moved from physiological curiosity to frontline therapy.2 Early enthusiasm followed the publication of the results of the 2015 FLORALI trial,
  Ary Serpa Neto
• Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease June 2, 2026
  IgG4-related disease has emerged as one of the clearest human models for understanding the role of B-lineage cells in immune-mediated inflammation. Although glucocorticoids remain effective for inducing remission, relapse during tapering is common, cumulative toxic effects are substantial, and durable disease control remains difficult to achieve. Della-Torre et al.1
  Thomas Dörner